New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:17 EDTMDTMedtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint
Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:17 EDTMDTSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
07:08 EDTMDTMedtronic pending acquisition of Covidien approved by Irish High Court
Subscribe for More Information
January 23, 2015
16:33 EDTMDTMedtronic reports 5.1% passive stake in Intersect ENT
Subscribe for More Information
15:46 EDTMDTPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTMDTMedtronic receives FDA approval for for the Medtronic Enterra II System
Subscribe for More Information
January 21, 2015
18:06 EDTMDTS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
January 12, 2015
13:02 EDTMDTMedtronic sees Coviden deal closing in last week of January, early February
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use